Vactosertib, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie's Disease
The World Journal of Men s Health2019Vol. 38(4), pp. 552–552
Citations Over TimeTop 17% of 2019 papers
Kang‐Moon Song, Doo Yong Chung, Min Ji Choi, Kalyan Ghatak, Nguyen Nhat Minh, Anita Limanjaya, Mi-Hye Kwon, Jiyeon Ock, Guo Nan Yin, Dae-Kee Kim, Ji-Kan Ryu, Jun‐Kyu Suh
Abstract
In view of the critical role of TGF-β and the Smad pathway in the pathogenesis of PD, inhibition of this pathway with an ALK5 inhibitor may represent a novel, targeted therapy for PD.
Related Papers
- → SMAD-Independent Down-Regulation of Caveolin-1 by TGF-β: Effects on Proliferation and Survival of Myofibroblasts(2015)47 cited
- → When the Smad signaling pathway is impaired, fibroblasts advance open wound contraction(2010)18 cited
- [Fibroblast and myofibroblast in the granulation tissue].(1977)
- → 031 Collagenase Injection Into the Peyronie’s Disease-Like Plaque in A Rat Model Reduces not Just Plaque Size, but Selectively Myofibroblast Content, and is Associated With Increased Apoptosis, Replicating the Effects of A PDE5 Inhibitor Given Separately, but not in Combination(2016)